- Clinical Trials
Genprex’s lead drug candidate, REQORSA™ Immunogene Therapy that uses our proprietary, non-viral ONCOPREX® Nanoparticle Delivery System was highlighted in a Key Opinion Leader event hosted by Alliance Global Partners (AGP) for their institutional customers.
Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial
Company achieves another milestone relating to its clinical trial strategy
Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).
Approval of new name marks important branding milestone and aligns with the program’s overall progress